Table 2.
Ongoing clinical trials for targeted therapies in advanced-stage cholangiocarcinomas.
| Treatment | Target(s) | Phase | Identifier |
|---|---|---|---|
| Gemcitabine + oxaliplatin + capecitabine vs. gemcitabine + oxaliplatin + panitumumab + capecitabine | EGFR | II | NCT00779454 |
| Gemcitabine + oxaliplatin + capecitabine + panitumumab or bevacizumab | EGFR − VEGFR | II | NCT01206049 |
| Trastuzumab + tipifarnib | HER2/neu + FTI | I | NCT00005842 |
| Varlitinib | EGFR | II | NCT02609958 |
| Gemcitabine + oxaliplatin + cetuximab + trastuzumab + gefitinib + lapatinib + sorafenib + crizotinib | Multiple targets | I/II | NCT02836847 |
| CART-EGFR | EGFR | I/II | NCT01869166 |
| Afatinib + capecitabine | EGFR | I | NCT02451553 |
| LY2801653 + cetuximab or cisplatin or gemcitabine or ramucirumab | Multiple targets | I | NCT01438554 |
| Pazopanib + GSK1120212 | Multiple targets | I | NCT01438554 |
| Sunitinib | Multiple targets | II | NCT01718327 |
| Gemcitabine + pazopanib | Multiple targets | II | NCT01855724 |
| Regorafenib | Multiple targets | II |
NCT02053376 NCT02162914 |
| Gemcitabine + oxaliplatin + regorafenib | Multiple targets | II | NCT02386397 |
| Ramucirumab | VEGFR | II | NCT02520141 |
| Ramucirumab + pembrolizumab | Multiple targets | I | NCT02443324 |
| Cediranib + AZD0530 | Multiple targets | I | NCT00475956 |
| Oxaliplatin + leucovorin calcium + fluorouracil + cediranib | Multiple targets | II | NCT01229111 |
| Sorafenib | VEGFR − PDGFR − BRAF | II | NCT00238212 |
| Sorafenib + oxaliplatin/capecitabine | VEGFR − PDGFR − BRAF | I/II | NCT00634751 |
| Ponatinib | FGFR | II |
NCT02265341 NCT02272998 |
| JNJ-42756493 | FGFR | I | NCT01703481 |
| BGJ398 | FGFR2 | II | NCT02150967 |
| ARQ087 | FGFR2 | II | NCT01752920 |
| FRA144 | FGFR2b | I | NCT02318329 |
| Ceritinib | ROS1 − ALK | II | NCT02638909 |
| Entrectinib | ROS1 − ALK | II | NCT02568267 |
| LDK378 (Ceritinib) | ROS1 − ALK | II | NCT02374489 |
| PLX8394 | BRAF | I/II |
NCT02428712 NCT02012231 |
| Gemcitabine + selumetinib vs gemcitabine | MEK | II | NCT02151084 |
| Refametinib | MEK | II | NCT02346032 |
| Trametinib vs 5-fluoruracil or capecitabine | MEK | II | NCT02042443 |
| Gemcitabine + MEK162 | MEK | II | NCT01828034 |
| Everolimus + gemcitabine | mTOR | I | NCT00949949 |
| Sirolimus + gemcitabine | mTOR | I | NCT01888302 |
| Copanlisib + gemcitabine | PI3K | II | NCT02631590 |
| AG-881 | IDH | I | NCT02481154 |
| AG-120 | IDH | I | NCT02073994 |
| AG-120 | IDH | III | NCT02989857 |
| Rucaparib + nivolumab | PARP | II | NCT03639935 |
| BBI-503 | STAT3 | II | NCT02232633 |
| Pembrolizumab + GM − CSF | PD1 | II | NCT02703714 |
| Pembrolizumab | PD1 | II | NCT02628067 |
| Pembrolizumab | PD1 | I/II | NCT02268825 |
| Nivolumab or Ipilimumab | PD1 − CTL4 | II | NCT02834013 |